EXACT SCIENCES CORPORATION

(EXAS)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
42.71 USD   +0.83%
08/10TRANSCRIPT : Exact Sciences Corporation Presents at UBS Genomics 2.0 and Medtech Innovations Summit 2022, Aug-10-2022 01:00 PM
CI
08/04WALL STREET STOCK EXCHANGE : Still seeing the glass half full
MS
08/04ANALYST RECOMMENDATIONS : Illinois Tool Works, Eaton, Marathon Petroleum, Microchip Technology, DuPont de Nemours...
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 13 61621 07013 4127 558--
Enterprise Value (EV)1 14 12020 57314 5619 5089 6769 662
P/E ratio -145x-23,6x-22,4x-10,1x-12,5x-18,7x
Yield ------
Capitalization / Revenue 15,5x14,1x7,59x3,75x3,29x2,83x
EV / Revenue 16,1x13,8x8,24x4,72x4,21x3,62x
EV / EBITDA -117x789x-77,4x-22,4x-34,9x-442x
Price to Book 5,97x7,09x3,94x2,53x2,83x2,99x
Nbr of stocks (in thousands) 147 232159 030172 319176 960--
Reference price (USD) 92,513277,842,742,742,7
Announcement Date 02/11/202002/16/202102/22/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 8761 4911 7672 0132 2972 670
EBITDA1 -12126,1-188-425-278-21,8
Operating profit (EBIT)1 -171-137-599-700-572-394
Operating Margin -19,5%-9,21%-33,9%-34,8%-24,9%-14,8%
Pre-Tax Profit (EBT)1 -269-857-843-767-640-445
Net income1 -84,0-849-596-757-611-403
Net margin -9,59%-56,9%-33,7%-37,6%-26,6%-15,1%
EPS2 -0,64-5,61-3,48-4,25-3,42-2,29
Dividend per Share2 ------
Announcement Date 02/11/202002/16/202102/22/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 474487522505507534
EBITDA1 -122-89,8-45,8-84,8-97,1-54,6
Operating profit (EBIT)1 -222-203-162-186-202-167
Operating Margin -46,9%-41,7%-31,1%-36,8%-39,9%-31,3%
Pre-Tax Profit (EBT)1 -225-183-168-200-219-186
Net income1 -221-181-166-197-213-180
Net margin -46,6%-37,2%-31,8%-39,1%-42,0%-33,7%
EPS2 -1,28-1,04-0,94-1,08-1,19-0,97
Dividend per Share ------
Announcement Date 02/22/202204/26/202208/02/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 504-1 1501 9502 1182 104
Net Cash position1 -497----
Leverage (Debt / EBITDA) -4,18x-19,1x-6,11x-4,59x-7,63x-96,4x
Free Cash Flow1 -28772,1-238-574-397-223
ROE (Net Profit / Equities) -5,66%-33,2%-21,2%-23,0%-23,5%-24,1%
Shareholders' equity1 1 4842 5562 8123 2952 5931 670
ROA (Net Profit / Asset) -3,34%-20,1%-10,3%-10,7%-10,1%-11,0%
Assets1 2 5154 2155 8057 1096 0453 667
Book Value Per Share2 15,518,719,816,915,114,3
Cash Flow per Share2 -0,880,82-0,60-2,22-1,35-0,12
Capex1 17264,4136182147166
Capex / Sales 19,6%4,31%7,68%9,05%6,41%6,23%
Announcement Date 02/11/202002/16/202102/22/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 7 557 942 081
Net sales (USD) 1 767 087 000
Number of employees 6 460
Sales / Employee (USD) 273 543
Free-Float 99,1%
Free-Float capitalization (USD) 7 490 678 615
Avg. Exchange 20 sessions (USD) 100 410 309
Average Daily Capital Traded 1,33%
EPS & Dividend